BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cyto Pulse Sciences, Inc., University Hospital Uppsala, and Cancer Center Karolinska Sign Agreement for Clinical Evaluation of Prostate Cancer DNA Vaccine


5/15/2007 1:40:10 PM

GLEN BURNIE, Md., May 15 /PRNewswire-USNewswire/ -- Cancer Center Karolinska, part of the Karolinska Institute, Stockholm, the highly regarded research and treatment center and Maryland firm Cyto Pulse Sciences have jointly developed a DNA Vaccine to stimulate a patient's immune system to fight and kill prostate cancer cells remaining in the body after removal or irradiation of the prostate gland. The safety of this DNA Vaccine will be evaluated in a clinical trial at the University Hospital Uppsala in Sweden using the Cyto Pulse Derma Vax(TM) DNA Vaccine delivery system.

Prostate cancer is diagnosed in more than 500,000 males every year in the United States and Europe. A common treatment is removal or irradiation of the prostate. Even with this radical procedure, approximately 25% of patients face recurrence of the disease.

"We are very pleased to have an agreement to conduct this very important evaluation," said Richard Walters, CEO of Cyto Pulse Sciences. "We have signed contracts to produce and test the DNA Vaccine and will submit the formal application to the Swedish Medical Products Agency shortly."

Cyto Pulse Sciences, Inc. is a biomedical device and treatment development company offering new, innovative technology and clinical therapeutic applications including the development and delivery of DNA vaccines. The company was founded in 1996 with the goal of developing clinical systems employing electric fields to create gene therapy and immunotherapeutic treatments unattainable by chemical or viral vectors. Its devices enable cellular material transfers and fusion with a degree of safety, repeatability and efficiency suitable for clinical use in gene therapy, immunotherapy, and hybridoma production.

Additional information on Cyto Pulse Sciences, Inc. is available at the company's website, http://www.cytopulse.com.

Cyto Pulse Sciences, Inc.

CONTACT: Tim Hurd of Cyto Pulse Sciences, Inc., +1-410-787-1890



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES